Portopulmonary Hypertension: From Bench to Bedside

Area of Science:

• Cardiology
• Hepatology
• Pulmonary Medicine

Background:

• Portopulmonary hypertension (PoPH) is pulmonary arterial hypertension (PAH) linked to portal hypertension.
• PoPH significantly increases morbidity and mortality in patients with liver disease or portal hypertension.
• Despite advances, PoPH survival remains worse than idiopathic PAH (IPAH).

Purpose of the Study:

• To review the epidemiology, pathophysiology, and clinical characteristics of PoPH.
• To highlight current management challenges and gaps in PoPH care.
• To explore potential future therapeutic strategies for PoPH.

Main Methods:

• Literature review focusing on PoPH pathogenesis, diagnosis, and treatment.
• Analysis of recent clinical trial data for PAH-specific therapies in PoPH patients.
• Discussion of clinical and hemodynamic features relevant to PoPH management.

Main Results:

• Recent trials show PAH-specific therapies improve hemodynamics and function in PoPH.
• Long-term survival benefits and impact on transplant outcomes with these therapies remain uncertain.
• Significant knowledge gaps persist in PoPH management strategies.

Conclusions:

• PAH-specific therapies offer initial promise for PoPH but require further long-term evaluation.
• Addressing management lacunae and exploring novel strategies are crucial for improving PoPH outcomes.
• Future research should focus on survival benefits and transplant outcomes in PoPH.